Emerging as a noteworthy breakthrough in the fight against obesity, Retatrutide is capturing considerable attention . This treatment combines the action of two known GLP-1 receptor agonists, liraglutide, plus an new glucose-dependent peptide component. Initial clinical data have demonstrated sign